U.S. Markets closed

Aoxing Pharmaceutical Announces Delisting and Deregistration of Common Stock

FOSTER CITY, CA / ACCESSWIRE / September 25, 2017 / Aoxing Pharmaceutical Company, Inc. (NYSE American: AXN) today announced that its board of directors has made a determination to remove the Aoxing Pharma Common Stock from the NYSE American. On September 25, 2017, Aoxing Pharma notified the NYSE American of its intention to file a Form 25 ("Notification of Removal from Listing and/or Registration under Section 12(b) of the Securities Exchange Act of 1934") with the Securities and Exchange Commission (the "SEC") on October 6, 2017. The purpose of the Form 25 filing is to affect the voluntary delisting from the NYSE American of Aoxing Pharma's outstanding Common Stock and the deregistration of the Common Stock under Section 12(b) of the Securities Exchange Act of 1934. The Company expects that the Form 25 filing will become effective on October 16, 2017. After the effectiveness of the Form 25 filing, Aoxing Pharma also intends to file a Form 15 with the SEC, requesting the suspension of the Company's reporting obligations under Sections 13(a) and 15(d) of the Exchange Act and the deregistration of its Common Stock under Section 12(g) of the Exchange Act.

The Board made the decision to remove the Common Stock from the NYSE American and to seek deregistration under the Exchange Act following its review and careful consideration of several factors, including the Company's inability to obtain equity financing during the past year, the ongoing listing, legal, administrative and accounting costs associated with being a publicly listed company, the risk that ongoing atrophy in the market price of the Common Stock will result in non-compliance with NYSE American continued listing requirements, and the amount of executive time and Company resources consumed in regulatory compliance obligations. The Board determined that delisting and deregistration are in the overall best interests of Aoxing Pharma and its stockholders.

Aoxing Pharma expects its Common Stock to begin trading on the OTC Market's Pink market tier following the effectiveness of the Form 25.

About the Company

Aoxing Pharmaceutical Company, Inc. is a U.S. incorporated pharmaceutical company with its operations in China, specializing in research, development, manufacturing, and distribution of a variety of narcotics and pain-management products. Headquartered in Shijiazhuang City, outside Beijing, Aoxing Pharma has the largest and most advanced manufacturing facility in China for highly regulated narcotic medicines. Its facility is one of the few GMP facilities licensed for the manufacture of narcotic medicines by the China Food and Drug Administration ("CFDA"). For more information, please visit: www.aoxingpharma.com.

Safe Harbor Statement

This press release contains certain statements that may include "forward-looking statements." All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and so these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including the risk factors discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on the SEC's website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Other than as required under the securities laws, the Company does not assume any duty to update these forward-looking statements.

Contact:

Aoxing Pharmaceutical Company:
646-367-1747
investor.relations@aoxingpharma.com

SOURCE: Aoxing Pharmaceutical Company